[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"reversal-of-neuromuscular-blockade\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:reversal-of-neuromuscular-blockade":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100607980","phase-1-a-single-ascending-dose-of-hrs-2162-in-healthy-subjects-100607980",false,"NCT07195604","A Single Ascending Dose of HRS-2162 in Healthy Subjects","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of HRS-2162 Injection in Healthy Subjects","Inclusion Criteria:\n\n1. The subjects voluntarily signed the informed consent form.\n2. Applicants must be between 18 and 45 years old at the time of signing the informed consent form, and both men and women are eligible .\n3. ASA classification is Grade I (only Parts Two and three)\n4. Male weight ≥50 kg, female weight ≥45 kg, body mass index between 19 and 28 kg\u002Fm ².\n5. Adopt efficient contraceptive measures\n\nExclusion Criteria:\n\n1. Those with a past or current clinical acute or chronic disease\n2. Those with a history of hereditary bleeding or coagulation disorders or non-traumatic bleeding .\n3. Those with a history of neuromuscular diseases or poliomyelitis\n4. Those with a history of anesthesia complications.\n5. Those whose laboratory test results during the screening period or baseline period exceed the normal range and have clinical significance\n6. The blood pressure of the subjects was abnormal and was judged by the researchers to be of clinical significance\n7. The subject has a history of severe systemic allergies for any reason.\n8. The subjects took steroid hormone drugs within 7 half-lives or 14 days before administrationSmoke ≥5 cigarettes per day within 3 months prior to the study.\n9. History of drug abuse.\n10. Those who the researchers considered unsuitable for inclusion",true,"ALL","18 Years","45 Years",{"count":21,"type":22},64,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The study is being conducted to evaluate the safety and tolerability of HRS-2162 injection in a single dose in healthy subjects, as well as the characteristics of PK\u002FPD",[28],"Reversal of Neuromuscular Blockade","RECRUITING","2025-11-14",{"date":32,"type":33},"2025-11-17","ACTUAL",{"date":35,"type":33},"2025-09-25",{"date":37,"type":22},"2025-12",{"name":39,"class":40},"Fujian Shengdi Pharmaceutical Co., Ltd.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":41},"100596341","phase-4-reversal-of-pipecuronium-induced-neuromuscular-blockade-with-sugammadex-during-sevoflurane-anesthesia-100596341","NCT07044193","Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Sevoflurane Anesthesia","Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Sevoflurane Anesthesia: a Drug Safety Randomised Controlled Trial","RPINMBWS","Inclusion Criteria:\n\n* 80 adult general surgery and neurosurgical patients are enrolled in the study after giving an informed written consent regarding their participation.\n* Age: between 18-65 years;\n* ASA score: 1-3;\n* BMI 18.5-25 (normal body weight);\n* Males and females were recruited in an equal ratio;\n* Minimal surgical time of at least ≥ 40 minutes;\n* Procedures requiring endotracheal intubation;\n\nExclusion Criteria:\n\n* Diseases affecting neuromuscular function (myopathies, severe liver and kidney failure);\n\n  * Drugs affecting neuromuscular function (magnesium, aminoglycosides);\n  * Difficult airway, or anticipated difficult intubation;\n  * Pregnancy (a pregnancy test is performed in women of childbearing age to rule out pregnancy);\n  * Breast-feeding;\n  * Acute surgery;\n  * COPD\n  * Glaucoma\n  * History of previous allergic\u002Fanaphylactic reactions","65 Years",{"count":52,"type":22},80,[54],"PHASE4","Safety during modern practice of anaesthesia is of great concern. Patients admitted daily for surgical procedures undergoing general anaesthesia for different types of operations are exposed to different risks, starting from the anaesthesia and ending with the surgical intervention. Aim of the study is to provide a comprehensive and evidence based data regarding the safety of the neuromuscular blocking agents used in modern anaesthesia practice, precisely Rocuronium and Pipecuronium, as well as the reversal agents such as Sugammadex, which is the sole agent in use in practice nowadays. A routine anaesthetic practice will be performed during the whole period of our study after strict patient selection criteria. Intraoperative standard monitoring as per local and international guidelines will be applied, this includes Spo2, ECG, NIBP\u002FIBP, etCO2, BIS and Tetragaph for neuromuscular blockade monitoring. After induction of anaesthesia and prior to the administration of the muscle relaxant agent, a TOFC (Train of Four Count) will be registered as the starting point. Throughout the anaesthetic time, there will be continuous TOF monitoring. The anaesthesia will be maintained by sevoflurane. Also, the recruited samples will be divided according to the neuromuscular blockade agents administered, either Rocuronium or Pipecuronium. At the end of the surgical procedure, the time lapse between the administration of the reversal agent Sugammadex and a TOF ratio of 0.9 is registered as our primary end point. TOF measures will be performed in the postoperative period, to make sure there is no residual neuromuscular blockade in the early postoperative phase. The study will not only monitor the safety of the neuromuscular blocking agents in use, but will also monitor any signs of anaphylaxis due to their administration both intra and postoperatively.",[57,58,28],"Neuromuscular Blocking Agents","Residual Neuromuscular Block",[60],"reversal of neuromuscular blockade","NOT_YET_RECRUITING","2025-06-27",{"date":64,"type":33},"2025-06-29",{"date":66,"type":22},"2025-06-26",{"date":68,"type":22},"2028-12-31",{"name":70,"class":71},"Tamas Vegh, MD","OTHER",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":41},"100577142","phase-1-recovery-times-of-half-dose-sugammadex-and-neostigmine-for-rocuronium-induced-neuromuscular-blockade-100577142","NCT06794450","Recovery Times of Half Dose Sugammadex and Neostigmine for Rocuronium-induced Neuromuscular Blockade","Comparison of Recovery Times Between 1 mg\u002Fkg Sugammadex and 60 mcg\u002Fkg Neostigmine for Moderate Neuromuscular Blockade Induced by Rocuronium in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients who underwent laparoscopic cholecystectomy under general anesthesia\n* Using muscle relaxant rocuronium\n* Aged 18-59 years\n* American Society of Anesthesiologists (ASA) physical status classification of 1 or 2.\n\nExclusion Criteria:\n\n* History of drug allergies to the agents used\n* Renal dysfunction\n* Musculoskeletal disorders\n* Central nervous system disorders\n* Difficult airways requiring intubation without the use of muscle relaxants.","59 Years",{"count":81,"type":22},60,[25,83],"PHASE2","In operating procedure with general anesthesia muscle relaxant is usually used to increase success rate of the operation and to give better outcome. The use of reversal drugs aims to reduce the risk of post-operative complications due to muscle relaxants. Neostigmine is commonly used as a reversal drug, but its indirect mechanism of action results in a long and unpredictable recovery time. Sugammadex directly bind and inactivate rocuronium, in which resulting in a faster and predictable recovery time. However, the high price limits the use of sugammadex.\n\nThis study aims to compare the effect of half dose sugammadex and neostigmine against the moderate neuromuscular blockade of rocuronium.\n\nThe main questions it aims to answer are:\n\nDoes half dose sugammadex gives faster recovery time? Researchers will compare sugammadex to neostigmine to see if sugammadex gives faster recovery time.\n\nParticipants will:\n\nBe given sugammadex or neostigmine as a reversal drug after the operation done",[57,28,86],"Recovery Time",[88,89,90],"Sugammadex","Neostigmine","recovery time from neuromuscular blockade","2025-01-25",{"date":93,"type":33},"2025-01-28",{"date":95,"type":33},"2024-11-05",{"date":97,"type":22},"2025-02",{"name":99,"class":71},"Universitas Padjadjaran"]